▲Wirig Diagram Hot
▲ ▲ ▼

What is Triple Negative Ductal Carcinoma?

By

Triple-negative ductal carcinoma is a specific type of breast cancer that accounts for approximately 15-20% of all breast cancer cases. It's called 'triple-negative' because the cancer cells test negative for three key receptors: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor 2 (HER2). Understanding this type of breast cancer is crucial for effective treatment and patient care.

Ductal carcinoma is the most common form of breast cancer, beginning in the milk ducts of the breast. When this type of cancer lacks the mentioned receptors, it's referred to as triple-negative ductal carcinoma. This article delves into the details of this condition, its characteristics, diagnosis,-stage, and treatment options.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a type of breast cancer that doesn't respond to certain hormonal therapies or drugs that target HER2 receptors. This is because the cancer cells lack these receptors, making it more difficult to treat compared to other types of breast cancer.

🩷 What does “Triple-Negative Breast Cancer” actually mean? Despite the name, triple-negative breast cancer (TNBC) isn’t defined by what it looks like on a mammogram or ultrasound it’s defined by what it doesn’t have. TNBC lacks: ❌ Estrogen receptors (ER) ❌ Progesterone receptors (PR) ❌ HER2 receptors Because it doesn’t have these receptors, treatment differs from other breast cancer subtypes. While TNBC can grow more quickly, advances in chemotherapy, immunotherapy, and targeted treatments... Diagnostic Medical Sonography, Ultrasound, Medical, Health
🩷 What does “Triple-Negative Breast Cancer” actually mean? Despite the name, triple-negative breast cancer (TNBC) isn’t defined by what it looks like on a mammogram or ultrasound it’s defined by what it doesn’t have. TNBC lacks: ❌ Estrogen receptors (ER) ❌ Progesterone receptors (PR) ❌ HER2 receptors Because it doesn’t have these receptors, treatment differs from other breast cancer subtypes. While TNBC can grow more quickly, advances in chemotherapy, immunotherapy, and targeted treatments... Diagnostic Medical Sonography, Ultrasound, Medical, Health
Infiltrating ductal Carcinoma, is the most common breast cancer.
Infiltrating ductal Carcinoma, is the most common breast cancer.
What is the Difference Between DCIS and Invasive Ductal Carcinoma
What is the Difference Between DCIS and Invasive Ductal Carcinoma

Research has shown that TNBC tends to be more aggressive and has a higher risk of recurring or metastasizing (spreading to other parts of the body) compared to other breast cancer types. The exact causes of TNBC are not yet fully understood, but certain factors increase the risk of developing this type of breast cancer.

Risk Factors for Triple-Negative Breast Cancer

Several factors can increase the risk of developing TNBC, including:

  • Family history of breast cancer, especially in close female relatives.
  • Inherited gene mutations, such as BRCA1 and BRCA2, which increase the risk of breast and ovarian cancer.
  • Personal history of breast cancer.
  • Certain hormonal factors, such as early menstruation, late menopause, and never having children.
  • Obesity, particularly in post-menopausal women.
  • Race or ethnicity; TNBC is more common in black women and women of Ashkenazi Jewish descent.

Incidence and Facts About Triple-Negative Breast Cancer

TNBC represents about 15-20% of all breast cancer cases. It's more common in younger women, with about half of all TNBC diagnoses occurring in women under the age of 50. However, it can occur at any age, including in men, although this is rare.

The incidence of TNBC varies among different populations. Black women are diagnosed with TNBC more often than white women, and Asians have the lowest incidence of TNBC.

Diagnosing Triple-Negative Ductal Carcinoma

Diagnosing triple-negative ductal carcinoma involves several tests and imaging procedures. Early detection is crucial for effective treatment and improving patient outcomes.

If a lump or other suspicious changes are found in the breast, a healthcare provider may order one or more of the following diagnostic tests:

Imaging Tests

Several imaging tests help locate the tumor and determine its size. These include:

  • Mammography
  • Breast ultrasound
  • Breast magnetic resonance imaging (MRI)

Biopsy

To confirm a breast cancer diagnosis and determine the type of cancer, a biopsy is performed. A small sample of the tumor is removed and analyzed in a laboratory. In some cases, the healthcare provider may perform a fine-needle aspiration or a core needle biopsy to remove cells or tissue.

After a breast cancer diagnosis, the healthcare team will determine the stage of the cancer. Staging helps determine the size of the tumor, whether it has spread, and the best course of treatment. The most common staging system used is the TNM system, which stands for tumor size, lymph node involvement, and metastasis (spread to distant organs).

Treating Triple-Negative Ductal Carcinoma

Due to the lack of hormone receptors and HER2 receptors, TNBC doesn't respond to hormonal therapies or targeted therapies like other breast cancer types. Therefore, the main treatment options for TNBC are surgery, radiation, and chemotherapy.

Surgery

Surgery plays a significant role in treating TNBC. The primary goal is to remove the cancerous tumor while conserving as much breast tissue as possible. The most common surgical procedures include:

  1. Lumpectomy: Removal of the tumor and a small amount of surrounding healthy tissue.
  2. Mastectomy: Removal of all, or a portion of, the breast.

Chemotherapy

Chemotherapy is the primary systemic treatment for TNBC. Systemic treatments travel through the bloodstream, reaching cancer cells throughout the body. Chemotherapy drugs target rapidly dividing cancer cells, preventing them from growing and multiplying. Chemotherapy for TNBC is often administered before surgery to shrink the tumor (neoadjuvant chemotherapy) or after surgery to destroy any remaining cancer cells (adjuvant chemotherapy).

Adjuvant Therapy

In some cases, additional treatments may be recommended after surgery to help destroy any remaining cancer cells and reduce the risk of recurrence. These can include:

  • Radiation therapy: Uses high-energy beams, usually X-rays, to destroy cancer cells.
  • Targeted therapies: Drugs that target specific gene changes found in some TNBC tumors, such as PARP inhibitors for BRCA-mutated TNBC.

Clinical trials offeranga please look at the entire blueprint

💬 Comments ↗ Share ★ Save
AD